Effect of α2-adrenoceptor blockade on lithium action in the rat brain

Brain Research

Volumn 994, Issue 1, 2003, Pages 73-80

  Laura Cuffi M ^a   Carbonell, Lourdes ^a   Mármol, Frederic ^a   Giménez, José ^a   Forn, Javier ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Brain 2D adrenoceptors; cAMP; Lithium chloride; Receptor turnover

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; ADENYLATE CYCLASE; ALPHA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; ISOPRENALINE; LITHIUM CHLORIDE; PRAZOSIN; RADIOLIGAND; TRITIUM; YOHIMBINE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; BRAIN MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ISOTOPE LABELING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY;

EID: 0344875104     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2003.09.019     Document Type: Article

References (46)

1. Avissar S., Schreiber G., Danon A., Belmaker R.H. Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex. Nature. 331:1988;440-442.
2. 2-adrenoceptors in the rat brain. Mol. Pharmacol. 42(5):1992;846-855.
3. 2-adrenergic receptors. Pharmacol. Biochem. Behav. 22(5):1985;835-843.
4. Bylund D.B., Snyder S.H. Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol. Pharmacol. 12(4):1976;568-580.
5. Bylund D.B., Eikenberg D.C., Hieble J.P., Langer S.Z., Lefkowitz R.J., Minneman K.P., Molinoff P.B., Ruffolo R.R. Jr., Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev. 46(2):1994;121-136.
6. Crews F.T., Paul S.M., Goodwin F.K. Acceleration of beta-receptor desensitization in combined administration of antidepressants and phenoxybenzamine. Nature. 290(5809):1981;787-789.
7. Ebstein R.P., Hermoni M., Belmaker R.H. The effect of lithium on noradrenaline-induced cyclic AMP accumulation in rat brain: inhibition after chronic treatment and absence of supersensitivity. J. Pharmacol. Exp. Ther. 213(1):1980;161-167.
8. 2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. Naunyn-Schmiedebergs Arch. Pharmacol. 343(5):1991;472-477.
9. Forn J., Valdecasas F.G. Effects of lithium on brain adenyl cyclase activity. Biochem. Pharmacol. 20(10):1971;2773-2779.
10. Forn J., Krueger B.K., Greengard P. Adenosine 3′,5′- monophosphate content in rat caudate nucleus: demonstration of dopaminergic and adrenergic receptors. Science. 186(4169):1974;1118-1120.
11. Geisler A., Klysner R. Combined effect of lithium and flupenthixol on striatal adenylate cyclase. Lancet. 1(8008):1977;430-431.
12. Haapalinna A., Viitamaa T., MacDonald E., Savola J.M., Tuomisto L., Virtanen R., Heinonen E. Evaluation of the effects of a specific alpha 2-adrenoceptor antagonist, atipamezole, on alpha 1- and alpha 2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. Naunyn-Schmiedebergs Arch. Pharmacol. 356(5):1997;570-582.
13. 2-Adrenergic agonist-induced inhibition of cyclic AMP formation in transfected cell lines using a microtiter-based scintillation proximity assay. J. Recept. Signal Transduct. Res. 15(1-4):1995;557-579.
14. Hedler L., Stamm G., Weitzell R., Starke K. Functional characterization of central alpha-adrenoceptors by yohimbine diastereomers. Eur. J. Pharmacol. 70(1):1981;43-52.
15. 2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex. Naunyn-Schmiedebergs Arch. Pharmacol. 357(6):1998;634-639.
16. Hsiao J.K., Manji H.K., Chen G.A., Bitran J.A., Risby E.D., Potter W.Z. Lithium administration modulates platelet Gi in humans. Life Sci. 50(3):1992;227-233.
17. Hudson C.J., Young L.T., Li P.P., Warsh J.J. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse. 13(3):1993;278-293.
18. 3H]prazosin. Eur. J. Pharmacol. 327(1):1997;79-86.
19. Jope R.S. A bimodal model of the mechanism of action of lithium. Mol. Psychiatry. 4(1):1999;21-25.
20. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry. 4(2):1999;117-128.
21. 2-adrenergic receptors: structure, function, and therapeutic implications. J. Pharmacol. Exp. Ther. 277(1):1996;10-16.
22. Lefkowitz R.J., Stadel J.M., Caron M.G. Adenylate cyclase coupled beta-adrenergic receptors: structure and mechanisms of activation and desensitization. Annu. Rev. Biochem. 52:1994;159-186.
23. 2-receptor classification. Mol. Pharmacol. 38(5):1990;599-603.
24. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
25. 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 18(6):1997;211-219.
26. 2-adrenoceptors: implications for receptor classification. Br. J. Pharmacol. 106(4):1992;1011-1018.
27. 2- Adrenoceptors: more subtypes but fewer functional differences. Trends Pharmacol. Sci. 15(4):1994;119-123.
28. Manji H.K. G proteins: implications for psychiatry. Am. J. Psychiatry. 149(6):1992;746-760.
29. Mármol F., Carbonell L., Cuffi M.L., Forn J. Demonstration of inhibition of cyclic AMP accumulation in brain by very low concentrations of lithium in the presence of α-adrenoceptor blockade. Eur. J. Pharmacol. 226(1):1992;93-96.
30. Masana M.I., Bitran J.A., Hsiao J.K., Potter W.Z. In vivo evidence that lithium inactivates Gi modulation of adenylyl cyclase in brain. J. Neurochem. 59(1):1992;200-205.
31. 1 adrenergic receptors in a non fusing muscle cell line. J. Biol. Chem. 257:1982;875-879.
32. McPherson G.A. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J. Pharmacol. Methods. 14(3):1985;213-228.
33. 2B-adrenoceptor subtypes. Br. J. Pharmacol. 98(3):1989;890-897.
34. Mørk A., Klysner R., Geisler A. Effects of treatment with a lithium-imipramine combination on components of adenylyl cyclase in the cerebral cortex of the rat. Neuropharmacology. 29(3):1990;261-267.
35. Mørk A., Geisler A., Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol. Toxicol. 71:1992;4-17.
36. Nahorski S.R., Ragan C.I., Challiss R.A. Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol. Sci. 12(8):1991;297-303.
37. 2-adrenergic receptor subtypes in rat brain: an in situ hybridization study. J. Comp. Neurol. 328:1993;575-594.
38. Osman O.T., Rudorfer M.V., Potter W.Z. Idazoxan: a selective alpha 2-antagonist and effective sustained antidepressant in two bipolar depressed patients. Arch. Gen. Psychiatry. 46(10):1989;958-959.
39. Puzantian T. Mirtazapine, an antidepressant. Am. J. Health-Syst. Pharm. 55(1):1998;44-49.
40. 2-adrenoceptor binding sites in rat brain. Eur. J. Pharmacol. 351(1):1998;145-154.
41. 2A-subtype. J. Neurochem. 63:1994;1077-1085.
42. 2D-adrenergic receptors in bovine pineal gland. Mol. Pharmacol. 40(2):1991;235-241.
43. Thams P., Geisler A. Influence of lithium on cyclic AMP accumulation in isolated rat fat cells. Acta Pharmacol. Toxicol. 45(5):1979;329-335.
44. 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol. Pharmacol. 45(3):1994;524-531.
45. 2-adrenoceptor, [erratum appears in 1993 Br. J. Pharmacol. 108 (3), 852]. Br. J. Pharmacol. 106(4):1992;986-995.
46. Zohar J., Ebstein R.P., Belmaker R.H. Adenylate cyclase as the therapeutic target site of lithium. Emrich H.M., Aldenhoff J.B., Lux H.D. Basic Mechamisms in the Action of Lithium. 1982;154-166 Excerpta Medica, Amsterdam.